This Article Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ash, D Search for Related Content PubMed PubMed Citation Articles by Ash, D

Advances in radiotherapy for prostate cancer

Department of Clinical Oncology, Cookridge Hospital, Hospital Lane, Leeds LS16 6QB, UK

View larger version (54K): [in a new window]   Figure 1. Schematic representation of the prostate implant. Seeds and needles are inserted according the x, y, and z co-ordinate as produced by the treatment plan.

View larger version (10K): [in a new window]   Figure 2. Actuarial prostate-specific antigen (PSA) relapse-free survival (RFS) for all 667 patients. The 8.2 years (98.2 months) PSA-RFS is 74.9%.

View larger version (18K): [in a new window]   Figure 3. Actuarial prostate-specific antigen (PSA) relapse-free survival according to pre-treatment PSA. PSA-RFS is 81.4%, 69.8%, and 36.3% for patients cohorts of PSA less or equal to 10, 10.1–20, and greater than 20, respectively (p<0.0001) (solid line, PSA10; dashed PSA 10.1–20; dotted PSA>20). Initial PSA is a predictive tool of PSA control.

View larger version (15K): [in a new window]   Figure 4. Actuarial prostate-specific antigen (PSA) relapse-free survival according to biopsy Gleason score. PSA-RFS is 78.3%, 66.5%, and 56.4% for patients cohorts of Gleason score less than 7, equal 7, and greater than 7, respectively (p<0.001) (solid line, Gleason<7; dashed Gleason=7; dotted Gleason>7). Gleason score is a predictive factor of PSA control.

View larger version (18K): [in a new window]   Figure 5. Actuarial prostate-specific antigen (PSA) relapse-free survival (RFS) according to ESTRO risk groups based on initial PSA and Gleason score prior to treatment. PSA-RFS is 84.3%, 73.9%, and 52.6% for patients cohorts of risk groups low, intermediate, and high, respectively (p0.0001) (solid line, low risk; dashed intermediate risk; dotted high risk).

View larger version (13K): [in a new window]   Figure 6. Actuarial prostate specific antigen (PSA) relapse-free survival (RFS) according pre-treatment hormones. PSA-RFS is 76.1%, for patients cohort being on pre-treatment hormones and 72.6% for patients not on hormone therapy (p=0.107) (solid line not on hormones; dashed line on hormones).